Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 9086 results
Found 9086 results.

Acquired Immunodeficiency Syndrome

Leger PD, Johnson DH, Robbins GK, et al. "Genome-wide association study of peripheral neuropathy with D-drug-containing regimens in AIDS Clinical Trials Group protocol 384." J. Neurovirol.. 2014;20(3):304-8.
Zolopa A, Andersen J, Powderly W, et al. "Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial." PLoS ONE. 2009;4(5):e5575.
DiFrancesco R, Rosenkranz S, A Mukherjee L, et al. "Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial." Ther Drug Monit. 2010;32(4):458-66.
Koelsch KK, Liu L, Haubrich R, et al. "Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro." J. Infect. Dis.. 2008;197(3):411-9.
Sun J, Nagaraj HN, Reynolds NR. "Discrete stochastic models for compliance analysis based on an AIDS Clinical Trial Group (ACTG) study." Biom J. 2007;49(5):731-41.
Robertson KR, Su Z, Margolis DM, et al. "Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort." Neurology. 2010;74(16):1260-6.
Hulgan T, Robbins GK, Kalams SA, et al. "T cell activation markers and African mitochondrial DNA haplogroups among non-Hispanic black participants in AIDS clinical trials group study 384." PLoS ONE. 2012;7(8):e43803.
Grady BJ, Samuels DC, Robbins GK, et al. "Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384." J. Acquir. Immune Defic. Syndr.. 2011;58(4):363-70.
Lehmann DS, Ribaudo HJ, Daar ES, et al. "Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols." Pharmacogenet. Genomics. 2015;25(2):51-9.
Hermes A, Squires K, Fredrick L, et al. "Meta-analysis of the safety, tolerability, and efficacy of lopinavir/ritonavir-containing antiretroviral therapy in HIV-1-infected women." HIV Clin Trials. 2012;13(6):308-23.
Zhang X, Tierney C, Albrecht M, et al. "Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146." Ther Drug Monit. 2013;35(2):209-16.
Flexner C. "HIV drug development: the next 25 years." Nat Rev Drug Discov. 2007;6(12):959-66.
Tenorio AR, Jiang H, Zheng Y, et al. "Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115." AIDS Res. Hum. Retroviruses. 2009;25(2):135-9.
Wilkin T, Lee JY, Lensing SY, et al. "High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine." HIV Clin Trials. 2013;14(2):75-9.
Sacktor N, Miyahara S, Evans S, et al. "Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment." J. Neurovirol.. 2014;20(6):620-6.


Funderburg NT, Andrade A, Chan ES, et al. "Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine." PLoS ONE. 2013;8(12):e83514.
Kang M, Hollabaugh K, Pham V, et al. "Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort." J. Acquir. Immune Defic. Syndr.. 2014;66(2):172-80.
Wyatt CM, Kitch D, Gupta SK, et al. "Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine." J. Acquir. Immune Defic. Syndr.. 2014;67(1):36-44.
Tungsiripat M, Kitch D, Glesby MJ, et al. "A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206." AIDS. 2010;24(11):1781-4.
Hu Z, Hatano H, Hammond SP, et al. "Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase." J. Acquir. Immune Defic. Syndr.. 2007;45(5):494-500.
Bartlett JA, Chen S-S, Quinn JB. "Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview." HIV Clin Trials. 2007;8(4):221-6.
Sax PE, Tierney C, Collier AC, et al. "Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results." J. Infect. Dis.. 2011;204(8):1191-201.
Torriani FJ, Komarow L, Parker RA, et al. "Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s." J. Am. Coll. Cardiol.. 2008;52(7):569-76.
Porter KA, Cole SR, Eron JJ, et al. "HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study." Antimicrob. Agents Chemother.. 2012;56(2):995-1000.
Shaffer D, Hughes MD, Sawe F, et al. "Cardiovascular disease risk factors in HIV-infected women after initiation of lopinavir/ritonavir- and nevirapine-based antiretroviral therapy in Sub-Saharan Africa: A5208 (OCTANE)." J. Acquir. Immune Defic. Syndr.. 2014;66(2):155-63.